PSMA ADC: Additional Phase II data

Data from 91 evaluable patients with metastatic CRPC in the open-label, U.S. Phase II PSMA ADC 2301 trial showed that 2.3 and 2.5 mg/kg IV PSMA ADC given every 3 weeks for up to 8 cycles led to 1 complete response and 5 partial responses, plus 72 cases of stable disease. Additionally, PSMA ADC reduced levels of CTCs by >=50% in 60 of 77 (78%) patients and reduced PSA levels by >=30% in 34 of 113 (30%) patients and by >=50% in 16 of 113 (14%) patients. In 29 evaluable chemotherapy-naive patients who have progressed on hormonal therapies, PSMA ADC led to 1 complete response and 4 partial responses, plus 22 cases of stable disease. In chemotherapy-naive patients, PSMA ADC reduced levels of CTCs by >=50% in 17 of 19 (89%) patients and reduced PSA levels by >=30% in 11 of 34 (32%) patients and by >=50% in 7 of 34 (21%) patients. ...